Navigation Links
Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference
Date:2/23/2012

management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015   Decision Resources ... differences in dialysis patient management in the U.S. ... submitted by U.S. and EU5 nephrologists from approximately ... binders are the most commonly used renal medications ... iron differs considerably between the two regions.      ...
(Date:7/7/2015)... , July 7, 2015 The ... USD 1,197.7 million by 2020, growing at an estimated CAGR ... study by Grand View Research, Inc. Introduction of innovative technologies ... with growing awareness levels pertaining to the advantages of breast ... next six years. In addition, presence of untapped growth opportunities ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... SAN RAFAEL, Calif. , Aug. 4 To ... companies have selected New Momentum, the leading SaaS-based anti-counterfeiting solution.  Both ... and shut down violators, their New Momentum solution will play a ... , , ...
... Aug. 4 Cytel Inc., premier provider of adaptive clinical trial ... software package for adaptive dose-finding studies based on frequentist or Bayesian methods. , ... The FDA,s recently issued adaptive trial guidelines ... level.  , , , ...
Cached Medicine Technology:Two More Global Pharmaceutical Companies Choose New Momentum to Stop Counterfeits 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 3
(Date:7/7/2015)... , ... July 07, 2015 , ... ... into everyday items, recently launched their first line of luxury smart jewelry called ... and is expected to ship this fall. , “The Socialite collection was ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... throughout the Southwest, including Giant, Mustang, Sun Dial and Howdy’s, raised more ... their original 2015 fundraising goal by nearly $100,000, to help support children ...
(Date:7/7/2015)... ... July 07, 2015 , ... This week Northeast Nebraska Imaging, ... website. The website’s goal is to provide patients with detailed information about the ... requesting appointments online. , Part of the center’s rebranding efforts, the website was ...
(Date:7/7/2015)... ... July 07, 2015 , ... Greatist today announced the ... helps active people find the most fun activities to do with friends. , The ... It also increases Greatist’s opportunity for events, e-commerce, and brand partnerships. , “I’ve been ...
(Date:7/7/2015)... ... July 07, 2015 , ... SC&H Group, a leading ... aims to give back to the community through company-wide volunteering efforts. , On an ... dedicate the day to assisting those in need throughout Baltimore and Washington D.C. ...
Breaking Medicine News(10 mins):Health News:WiseWear Unveils Luxury Smart Jewelry Line 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:SC&H Group Celebrates 9th Annual Day of Service 2
... , , YSA and ... , , WASHINGTON, Aug. 10 ... the second year to offer UnitedHealth HEROES grants to youth-led ... Educators, service-learning coordinators, and students in the health professions are ...
... Long-standing liver disease has long been recognized to result ... various international studies, the overall incidence has varied from ... However, the reason for this is poorly understood. With ... and offering complete cure and long-term survival, bone disease ...
... age than is normal, researchers note , MONDAY, Aug. 10 ... the attacks on the Twin Towers on 9/11 may be ... blood. , Notably, half of the cases identified among law ... is usually a disease of the elderly. , "This ...
... , , , , ... now participate in the advanced stuttering treatment program at Hollins Communications ... at a substantially reduced cost through 2009 thanks to new stuttering ... , HCRI,s scholarship program is designed to broaden accessibility ...
... RONKONKOMA, N.Y., Aug. 10 NBTY, Inc. (NYSE: ... marketer of nutritional supplements, today announced that it will web cast the ... the Canaccord Adams Global Growth Conference in Boston on Thursday, ... to be web cast live on the Company Web site, ...
... , ROCHESTER, N.Y., Aug. 10 Your sleeping problems ... as Fibromyalgia (FM), and Chronic Fatigue Syndrome (CFS). But it can ... , , Recent studies show that ... review written by Professor Mark Opp from the University of Michigan ...
Cached Medicine News:Health News:Youth Find Innovative Solutions to Leading Health Threat 2Health News:Youth Find Innovative Solutions to Leading Health Threat 3Health News:Youth Find Innovative Solutions to Leading Health Threat 4Health News:9/11 Responders May Be At Raised Myeloma Risk 2Health News:9/11 Responders May Be At Raised Myeloma Risk 3Health News:Hollins Communications Research Institute Announces More Stuttering Therapy Scholarships 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 3Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 2Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 3
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: